Adenosine monophosphate-activated protein kinase and nitric oxide in rat steatotic liver transplantation

Carrasco-Chaumel, E.; Roselló‐Catafau, Joan; Bartrons, Ramón; Franco-Gou, Rosa; Xaus, Carme; Casillas, Arani; Gelpí, Emili; Rodés, Joan; Peralta, Carmen

doi:10.1016/j.jhep.2005.05.021

Cited by 70 publications

(116 citation statements)

References 48 publications

Supporting

Mentioning

106

Contrasting

Order By: Relevance

“…PC also has the potential to increase the number of organs suitable for LT since it can improve the outcome for marginal grafts that would not otherwise have been transplanted. Its benefits to reduce the vulnerability of steatotic grafts to I/R injury have also been reported in different experimental studies of LT (Carrasco et al, 2005;Fernández et al, 2004). Interestingly, the effectiveness of PC in clinical practice in major liver hepatectomy opens up new possibilities in living donor liver transplantation, since the ischemia period is similar in both surgical procedures.…”

Section: Surgical Strategiesmentioning

confidence: 80%

“…Thus, caspase inhibition, a highly protective strategy in non-steatotic livers, had no effect on hepatocyte injury in steatotic livers (Selzner et al, 2000). For instance, whereas in an LT experimental model a NO donor reduced oxidative stress in non-steatotic livers, the same dose increased vulnerability of steatotic grafts to I/R injury (Carrasco et al, 2005). The injurious effects of exogenous NO donors on hepatic injury and oxidative stress in steatotic grafts could be explained by peroxinitrite generation caused by ROS overproduction (Carrasco et al, 2005).…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

“…(Sp, species). (Carini et al, 2004;Carrasco et al, 2005;Casillas et al, 2006;Chavin et al, 2004;Cheng et al, 2003;Esfandiari et al, 2007;Fan et al, 1999;Hassan et al, 2008;Massip-Salcedo et al, 2006;Nakano et al, 2007;Natori et al, 1999;Peralta et al, 2001aPeralta et al, , 2001bPolyak et al, 2000;Reynaert et al, 2005;Schmidt, 2010;Selzner et al, 2000Selzner et al, , 2003Vajdova et al, 2002;Yoshinari et al, 2001) The difficulty of blocking the inflammation related to this process must be taken into account because, among other factors, many mediators and cell types are involved in this kind of inflammatory response. Pharmacological treatment-derived difficulties must also be considered.…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

“…For instance, whereas in an LT experimental model a NO donor reduced oxidative stress in non-steatotic livers, the same dose increased vulnerability of steatotic grafts to I/R injury (Carrasco et al, 2005). The injurious effects of exogenous NO donors on hepatic injury and oxidative stress in steatotic grafts could be explained by peroxinitrite generation caused by ROS overproduction (Carrasco et al, 2005). HO-1 activators such as cobalt (III) protoporphyrin IX, might protect both liver types against warm I/R injury.…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

“…Similarly to the benefits of TMZ, the addition of AMPK activators to UW solutions such as 5-amino-4-imidazole carboxamide riboside (AICAR), protected steatotic livers against their vulnerability to I/R. TMZ, by means of AMPK, increased NO, thus protecting steatotic livers against their vulnerability to I/R injury Carrasco et al, 2005). Taking these observations into account, TMZ and AICAR may constitute new additives to UW solution in steatotic liver preservation, whereas a combination of both seems unnecessary.…”

Section: Trimetazidine and Aicarmentioning

confidence: 99%

See 4 more Smart Citations

Ischemia-Reperfusion Injury Associated with Liver Transplantation in 2011: Past and Future

Elias-Miró¹,

Jiménez‐Castro²,

Peralta³

2012

Liver Transplantation - Basic Issues

View full text Add to dashboard Cite

Section: Surgical Strategiesmentioning

confidence: 80%

Section: Pharmacological Treatmentmentioning

confidence: 99%

Section: Pharmacological Treatmentmentioning

confidence: 99%

Section: Pharmacological Treatmentmentioning

confidence: 99%

Section: Trimetazidine and Aicarmentioning

confidence: 99%

See 3 more Smart Citations

Ischemia-Reperfusion Injury Associated with Liver Transplantation in 2011: Past and Future

Elias-Miró¹,

Jiménez‐Castro²,

Peralta³

2012

Liver Transplantation - Basic Issues

View full text Add to dashboard Cite

Preservation of steatotic livers in IGL-1 solution

et al. 2006

Self Cite

View full text Add to dashboard Cite

A new Institut Georges Lopez (IGL-1) solution was used to preserve steatotic livers. Steatotic (obese [Ob]) and nonsteatotic (lean [Ln]) livers from Zü cker rats (n ϭ 16, 8 Ln and 8 Ob) were preserved for 24 hours at 4°C in University of Wisconsin (UW) or IGL-1 solution, respectively, and then perfused ex vivo for 2 hours at 37°C. Additionally, Ob and Ln livers (n ϭ 16, 8 Ln and 8 Ob) were preserved in IGL-1 plus N-nitro-L-arginine methyl ester hydrochloride (L-NAME). Hepatic injury and function (aminotransferases, bile production, bromosulfophthalein clearance), and factors potentially involved in the susceptibility of steatotic livers to ischemia-reperfusion injury, such as oxidative stress, mitochondrial damage, and vascular resistance, were studied. Nitric oxide (NO) production and constitutive and inducible NO synthase were also measured. Steatotic and nonsteatotic livers preserved in IGL-1 solution showed lower transaminases, malondialdehyde, glutamate dehydrogenase levels, and higher bile production than UW-solution-preserved livers. IGL-1 solution protected against oxidative stress, mitochondrial damage and the alterations in vascular resistance associated with cold ischemia-reperfusion. Thus, at the end of reperfusion period, aspartate aminotransferase levels in steatotic livers were 281 Ϯ 6 U/L in UW vs. 202 Ϯ 10 U/L in IGL-1 solution. Glutamate dehydrogenase was 463 Ϯ 75 U/L in UW vs. 111 Ϯ 4 U/L in IGL-1 solution, and oxidative stress was 3.0 Ϯ 0.1 nmol/mg prot in UW vs. 2.0 Ϯ 0.1 nmol/mg prot in IGL-1 solution. These beneficial effects of IGL-1 solution were abolished by the addition of L-NAME, which implicates NO in the benefits of IGL-1. In conclusion, IGL-1 solution provided steatotic livers with better protection against the deleterious effects of cold ischemia-reperfusion injury than did UW solution.

show abstract

Addition of adenosine monophosphate-activated protein kinase activators to University of Wisconsin solution: A way of protecting rat steatotic livers

et al. 2007

Self Cite

View full text Add to dashboard Cite

This study investigates how the addition of trimetazidine (TMZ) and aminoimidazole-4-carboxamide ribonucleoside (AICAR) to University of Wisconsin (UW) solution protects steatotic livers. Steatotic and nonsteatotic livers were preserved for 24 hours at 4°C in UW and UW with TMZ and AICAR (separately or in combination) and then perfused ex vivo for 2 hours at 37°C. Adenosine monophosphate-activated protein kinase (AMPK) or nitric oxide (NO) synthesis inhibition in livers preserved in UW with TMZ was also investigated. Hepatic injury and function (transaminases, bile production, and sulfobromophthalein clearance) and factors potentially involved in the susceptibility of steatotic livers to ischemia-reperfusion (I/R), including vascular resistance, mitochondrial damage, adenosine triphosphate depletion, and oxidative stress were evaluated. AMPK, NO synthase (NOS), nitrate, and nitrite levels were also determined. The addition of TMZ and AICAR (separately or in combination) to UW reduced hepatic injury, improved functionality, and protected against the mechanisms responsible for the vulnerability of steatotic livers to I/R. Like AICAR, TMZ increased AMPK, constitutive NOS, and nitrates and nitrites, and conversely, AMPK or NO synthesis inhibition abolished the benefits of TMZ. In conclusion, TMZ, by means of AMPK, increased NO, thus protecting steatotic livers against their vulnerability to I/R injury. TMZ and AICAR may constitute new additives to UW solution in steatotic liver preservation, whereas a combination of both seems unnecessary. Liver Transpl 13:410-425, 2007.

show abstract

Adenosine monophosphate-activated protein kinase and nitric oxide in rat steatotic liver transplantation

Cited by 70 publications

References 48 publications

Ischemia-Reperfusion Injury Associated with Liver Transplantation in 2011: Past and Future

Ischemia-Reperfusion Injury Associated with Liver Transplantation in 2011: Past and Future

Preservation of steatotic livers in IGL-1 solution

Addition of adenosine monophosphate-activated protein kinase activators to University of Wisconsin solution: A way of protecting rat steatotic livers

Contact Info

Product

Resources

About